Viridian Therapeutics
VRDN
22 hedge funds and large institutions have $36.6M invested in Viridian Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 15 closing their positions.
338% more capital invested
Capital invested by funds: $8.36M → $36.6M (+$28.3M)
55.71% more ownership
Funds ownership: 1.27% → 56.98% (+56%)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 26 → 22 (-4)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.29M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$6.81M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.42M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.4M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.01M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$284K |
| 3 |
JP Morgan Chase
New York
|
-$255K |
| 4 |
VF
Virtu Financial
New York
|
-$87K |
| 5 |
BlackRock
New York
|
-$86.8K |
VRDN Hedge Fund Activity: Q4 2020 in Review
22 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2020, worth a combined $36.6M — up 338% from $8.36M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of VRDN and 11 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Logos Global Management, opening a new position worth an estimated $8.29M. The largest seller was Fidelity Investments, exiting entirely with an estimated $3.01M sold.
- 22 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2020, down from 26 in Q3 2020.
- Funds reported $36.6M of Viridian Therapeutics stock for Q4 2020, up 338% quarter-over-quarter.
- 11 funds opened new Viridian Therapeutics positions in Q4 2020 and 15 closed out, a net change of -4 holders.
- The largest Viridian Therapeutics buyer in Q4 2020 was Logos Global Management, an estimated $8.29M added.
- The largest Viridian Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $3.01M sold.
Based on aggregated 13F filings for Q4 2020.